A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders

Autor/inn/en	Bhatti, Irfan; Thome, Andrew; Smith, Patricia Oxler; Cook-Wiens, Galen; Yeh, Hung Wen; Gaffney, Gary R.; Hellings, Jessica A.
Titel	A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders
Quelle	In: Journal of Autism and Developmental Disorders, 43 (2013) 5, S.1017-1027 (11 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-012-1647-0
Schlagwörter	Hyperactivity; Autism; Pervasive Developmental Disorders; Drug Therapy; Youth; Symptoms (Individual Disorders); Outcomes of Treatment; Aggression + Suchen Sie Ihr Suchwort? Hyperaktivität; Autismus; Jugend; Jugendlicher; Jugendalter; Psychiatrische Symptomatik
Abstract	We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6-17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed [greater than or equal to]3 ADHD medications. Mean dose was 1.3 [plus or minus] 0.6 mg/kg/day, mean trough level 114.1 [plus or minus] 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was [less than or equal to]2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury. (As Provided).
Anmerkungen	Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: service-ny@springer.com; Web site: http://www.springerlink.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10